H. pylori Eradication Did Not Result in Platelet Recovery for All Chronic ITP Cases

Share this content:
The patients who did respond following the eradication of infection, however, had responses up to 1 year.
The patients who did respond following the eradication of infection, however, had responses up to 1 year.

Among patients in Brazil with idiopathic thrombocytopenic purpura (ITP), there was little platelet recovery after the eradication of Heliobacter pylori infection, a new study showed.1

Of the patients in the study successfully treated for H. pylori, only 30% had increased platelet counts at 6 months. However, the effect on platelet counts remained for at least as 1-year follow-up, according to the study.

“These results suggest that treating H. pylori infection might be worthwhile in a subset of chronic ITP patients,” they wrote.

Continue Reading Below

The small study included 28 patients with chronic ITP. The majority of patients (78.5%) were H. pylori-positive, a rate similar to that found in the general population, the authors said. Of the 22 positive patients, 15 were treated for the infection; 86% had the infection cleared with standard triple therapy.

At 6 months, 4 of 13 patients (30%) had an increase in platelet count.

Previous studies had suggested that differences in clinical findings between responders and nonresponders might be due to baseline characteristics; however, the researchers found that platelet response was not linked with mean baseline platelet count, duration of chronic ITP, gender, age, previous use of medication, or splenectomy.

Reference

  1. De Castro Barbosa AM, Ribeiro RA, Silva CISM, et al. Platelet count response to Helicobaster pylori eradication for idiopathic thrombocytopenic purpura in northeastern Brazil. Hematol Transfus Cell Ther. 2018;40:12-17.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs